Connect Biopharma Holdings (CNTB) Interest & Investment Income (2024 - 2026)

Connect Biopharma Holdings (CNTB) has reported Interest & Investment Income for 3 consecutive years, with $260000.0 the latest figure, recorded in Q1 2026.

• Quarterly Interest & Investment Income fell 63.89% year-over-year to $260000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 53.95% YoY) and the FY2025 annual result came in at $2.3 million, down 49.07% from the prior year.
• Interest & Investment Income eased to $260000.0 in Q1 2026 per CNTB's latest filing, from $384000.0 in the prior quarter.
• Over the last five years, Interest & Investment Income for CNTB reached as high as $1.2 million in Q1 2024 and fell as low as $260000.0 in Q1 2026.
• A 3-year average of $775666.7 and a median of $720000.0 in 2025 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2025 — Interest & Investment Income plunged 42.26% — and 2026, when it plunged 63.89%.
• Year by year, Interest & Investment Income stood at $849000.0 in 2024, then tumbled by 54.77% to $384000.0 in 2025, then slumped by 32.29% to $260000.0 in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $260000.0, $384000.0, and $545000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.